Paroxetine with pindolol augmentation: A double-blind, randomized, placebo-controlled study in depressed in-patients

European Neuropsychopharmacology

Volumn 18, Issue 2, 2008, Pages 141-146

  Geretsegger, Christian ^a   Bitterlich, Waltraud ^a   Stelzig, Renate ^a   Stuppaeck, Christoph ^a   Bondy, Brigitta ^b   Aichhorn, Wolfgang ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

^b LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

Augmentation; Bipolar disorder; Depression; Paroxetine; Pindolol

Indexed keywords

ANTIDEPRESSANT AGENT; MOOD STABILIZER; NORADRENALIN UPTAKE INHIBITOR; PAROXETINE; PINDOLOL; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TETRACYCLIC ANTIDEPRESSANT AGENT; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; AGITATION; ANOREXIA; ARTICLE; BIPOLAR DISORDER; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE DURATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; KAPLAN MEIER METHOD; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SIDE EFFECT; SLEEP DISORDER; STATISTICAL ANALYSIS; SWEATING; TREATMENT RESPONSE;

ADULT; DEPRESSION; DOUBLE-BLIND METHOD; DRUG EVALUATION; DRUG SYNERGISM; FEMALE; HUMANS; INPATIENTS; MALE; MIDDLE AGED; PAROXETINE; PINDOLOL; SEROTONIN ANTAGONISTS; SEROTONIN UPTAKE INHIBITORS; STATISTICS, NONPARAMETRIC; TIME FACTORS;

EID: 37349087861     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2007.09.002     Document Type: Article

References (32)

1. Altshuler L.L., Frye M.A., and Gitlin M.J. Acceleration and augmentation strategies for treating bipolar depression. Biol.Psychiatry 53 (2003) 691-700
2. Artigas F. 5-HT and antidepressants: new views from microdialysis studies. Trends Pharmacol. Sci. 14 (1993) 262
3. Artigas F., Perez V., and Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch. Gen. Psychiatry 51 (1994) 248-251
4. Artigas F., Romero L., de Montigny C., and Blier P. Acceleration of the effect of selected antidepressant drugs in major depression by 5-HT1A antagonists. Trends Neurosci. 19 (1996) 378-383
5. Berman R.M., Darnell A.M., Miller H.L., Anand A., and Charney D.S. Effect of pindolol in hastening response to fluoxetine in the treatment of major depression: a double-blind, placebo-controlled trial. Am. J. Psychiatry 154 (1997) 37-43
6. Blier P. The pharmacology of putative early-onset antidepressant strategies. Eur. Neuropsychopharmacol. 13 (2003) 57-66
7. Cremers T.I., Wiersma L.J., Bosker F.J., den Boer J.A., Westerink B.H., and Wikstrom H.V. Is the beneficial antidepressant effect of coadministration of pindolol really due to somatodendritic autoreceptor antagonism?. Biol. Psychiatry 50 (2001) 13-21
8. Fernandes E., Gomes A., Costa D., and Lima J.L. Pindolol is a potent scavenger of reactive nitrogen species. Life Sci. 77 (2005) 1983-1992
9. Gruwez B., Dauphin A., and Tod M. A mathematical model for paroxetine antidepressant effect time course and its interaction with pindolol. J. Pharmacokinet. Pharmacodyn. 32 (2005) 663-683
10. Haberl F., Deisenhammer E.A., Aichhorn W., Geretsegger C., and Stuppaeck C. Eine neue Nebenwirkungsskala für Antidepressiva. Neuropsychiatrie 14 2 (2000) 132 Ref Type: Abstract
11. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 23 (1960) 56-62
12. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int. Clin. Psychopharmacol. 9 Suppl 1 (1994) 19-26
13. Lingjaerde O., Ahlfors U.G., Bech P., Dencker S.J., and Elgen K. The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr. Scand., Suppl. 334 (1987) 1-100
14. Maes M., Libbrecht I., van Hunsel F., Campens D., and Meltzer H.Y. Pindolol and mianserin augment the antidepressant activity of fluoxetine in hospitalized major depressed patients, including those with treatment resistance. J. Clin. Psychopharmacol. 19 (1999) 177-182
15. Martinez D., Hwang D., Mawlawi O., Slifstein M., Kent J., Simpson N., Parsey R.V., Hashimoto T., Huang Y., Shinn A., Van Heertum R., Abi-Dargham A., Caltabiano S., Malizia A., Cowley H., Mann J.J., and Laruelle M. Differential occupancy of somatodendritic and postsynaptic 5HT(1A) receptors by pindolol: a dose-occupancy study with [11C]WAY 100635 and positron emission tomography in humans. Neuropsychopharmacology 24 (2001) 209-229
16. Montgomery S.A., and Asberg M. A new depression scale designed to be sensitive to change. Br. J. Psychiatry 134 (1979) 382-389
17. Moreno F.A., Gelenberg A.J., Bachar K., and Delgado P.L. Pindolol augmentation of treatment-resistant depressed patients. J. Clin. Psychiatry 58 (1997) 437-439
18. National Institute of Mental Health. CGI. Clinical Global Impressions. In: Guy W., and Bonato R.R. (Eds). Manual for the ECDEU Assessment Battery. Rockville, Chevy Chase (1970)
19. Overall J.E., and Atlas R.S. Survival analysis with unreliable endpoints. J. Psychiatr. Res. 31 (1997) 383-392
20. Perez V., Gilaberte I., Faries D., Alvarez E., and Artigas F. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. Lancet 349 (1997) 1594-1597
21. Perez V., Soler J., Puigdemont D., Alvarez E., and Artigas F. A double-blind, randomized, placebo-controlled trial of pindolol augmentation in depressive patients resistant to serotonin reuptake inhibitors. Grup de Recerca en Trastorns Afectius. Arch. Gen. Psychiatry 56 (1999) 375-379
22. Perez V., Puiigdemont D., Gilaberte I., Alvarez E., and Artigas F. Augmentation of fluoxetine's antidepressant action by pindolol: analysis of clinical, pharmacokinetic, and methodologic factors. J. Clin. Psychopharmacol. 21 (2001) 36-45
23. Perry E.B., Berman R.M., Sanacora G., Anand A., Lynch-Colonese K., and Charney D.S. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. J. Clin. Psychiatry 65 (2004) 238-243
24. Quitkin F.M., Rabkin J.G., Ross D., and Stewart J.W. Identification of true drug response to antidepressants. Use of pattern analysis. Arch. Gen. Psychiatry 41 (1984) 782-786
25. Romero L., Celada P., and Artigas F. Reduction of in vivo striatal 5-hydroxytryptamine release by 8-OH-DPAT after inactivation of Gi/G(o) proteins in dorsal raphe nucleus. Eur. J. Pharmacol. 265 (1994) 103-106
26. Scuvee-Moreau J.J., and Dresse A.E. Effect of various antidepressant drugs on the spontaneous firing rate of locus coeruleus and dorsal raphe neurons of the rat. Eur. J. Pharmacol. 57 (1979) 219-225
27. Smeraldi E., Benedetti F., Barbini B., Campori E., and Colombo C. Sustained antidepressant effect of sleep deprivation combined with pindolol in bipolar depression. A placebo-controlled trial. Neuropsychopharmacology 20 (1999) 380-385
28. Sokolski K.N., Conney J.C., Brown B.J., and DeMet E.M. Once-daily high-dose pindolol for SSRI-refractory depression. Psychiatry Res. 125 (2004) 81-86
29. Stassen H.H., Delini-Stula A., and Angst J. Time course of improvement under antidepressant treatment: a survival-analytical approach. Eur. Neuropsychopharmacol. 3 (1993) 127-135
30. Tome M.B., Isaac M.T., Harte R., and Holland C. Paroxetine and pindolol: a randomized trial of serotonergic autoreceptor blockade in the reduction of antidepressant latency. Int. Clin. Psychopharmacol. 12 (1997) 81-89
31. Zanardi R., Artigas F., Franchini L., Sforzini L., Gasperini M., Smeraldi E., and Perez J. How long should pindolol be associated with paroxetine to improve the antidepressant response?. J. Clin. Psychopharmacol. 17 (1997) 446-450
32. Zanardi R., Franchini L., Gasperini M., Lucca A., Smeraldi E., and Perez J. Faster onset of action of fluvoxamine in combination with pindolol in the treatment of delusional depression: a controlled study. J. Clin. Psychopharmacol. 18 (1998) 441-446